ASCO GUIDELINES Bundle

Hormone Receptor Positive Metastatic Breast Cancer - Endocrine Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/770592

Contents of this Issue

Navigation

Page 9 of 9

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2016 All rights reserved Disclaimer is pocket card is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket card does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/guidelines/ advancedendocrinebreast. Copyright © 2016 by American Society of Clinical Oncolog y. All rights reserved. ASCOHREN16113 Abbreviations AI, aromatase inhibitor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HER2+, human epidermal growth factor receptor 2-positive; HR+, hormone receptor-positive; MBC, metastatic breast cancer; OS, ovarian function suppression; PFS, progression-free survival; PR, progesterone receptor, qd, daily; tid, three times a day Source Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine erapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncolog y Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069-3103. Recommendation Grading Type Benefit/harm Evidence Quality Strength Of Recommendation EB Evidence-based B Benefits outweigh harms H High S Strong CB Consensus- based H Harms outweigh benefits I Intermediate M Moderate L Low W Weak ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, patient versions, frequently asked questions, and other clinical tools and resources, is available at www.asco.org/guidelines/advancedendocrinebreast and www.asco.org/guidelineswiki

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Hormone Receptor Positive Metastatic Breast Cancer - Endocrine Therapy